Highlights from ESMO TAT 2025

With the ESMO Targeted Anticancer Therapies Congress (3–5 March 2025, Paris, France) wrapped up, we are delighted to share key themes from this year's event. This multi-stakeholder forum brought together researchers, industry partners, investors and regulatory bodies, making it a key event for professionals involved in the development of anticancer drugs.  Conference highlights Innovations in Phase I study design and the rise of virtual drug development Big data is emerging as a key player for informing early drug discovery, particularly in identifying new combination therapies. Megan Gibbs (AstraZeneca, MA, USA) highlighted that predictive models are becoming more sophisticated, offering valuable...